Anaemia of CKD has a substantial impact on patients’ lives1
It is associated with poor clinical outcomes and reduced quality of life.1,2
This site is intended only for Healthcare Professionals, particularly those who are experienced in the management of anaemia associated with chronic kidney disease.
The website you have tried to access contains clinical information designed specifically for medical professionals experienced in treating this condition. If you have any questions about your health or treatment, please consult your doctor.
Anaemia of CKD has a substantial impact on patients’ lives1
It is associated with poor clinical outcomes and reduced quality of life.1,2
Symptoms of anaemia overlap with those of CKD1 and may add to the burden of CKD.2
Untreated anaemia may accelerate progression of CKD.1,3
Current management of CKD can be sub-optimal2,4
Some patients with anaemia of CKD are not treated to target3-5
Concern about the risks of over-correcting haemoglobin may lead to under-treatment of patients.4
Effective control of Hb?
Convenience?
Tolerability?
CKD, chronic kidney disease; GI, gastrointestinal; Hb, haemoglobin.
References
At home with their treatment.
Oral treatment that can be taken at home1
no special storage instructions1
no need to administer in hospital1
Three times weekly dosage1
Reduced use of IV iron compared with ESA1
CKD, chronic kidney disease; DD, dialysis-dependent; ESA, erythropoiesis-stimulating agent; IV, intravenous; NDD, non-dialysis-dependent; TIW, three times weekly.
Reference
Routine oral iron
Iron replete
Hb below target
Poor adherence to oral iron
Routine IV iron
Iron replete
Hb below target
Difficulty attending
clinic for IV iron
EVRENZO is an oral tablet that provides Hb correction and maintenance superior to placebo (p<0.0001) and comparable to ESA (p=0.844), with reduced use of IV iron1
Routine iron
Iron replete
Hb below target
EVRENZO is an oral tablet that provides comparable Hb correction (95% CI; 0.28 [0.110, 0.451]) and maintenance (95% CI; 0.30 [0.228, 0.373]) to ESA, with reduced use of IV iron1
How can your patients get more out of EVRENZO?
The leaflets below provide educational materials and simple advice to support patients during their treatment journey.
A general information for patients having anaemia of CKD, information about what is anaemia, symptoms, tests etc, and include a diary for the patients to make their notes for the next clinic visit
Information for patients prescribed EVRENZO, informing about anaemia, what is EVRENZO, administration, side effects etc - and include a diary for the patients to make their notes for the next clinic visit
DD, dialysis-dependent; ESA, erythropoiesis-stimulating agent; Hb, haemoglobin; IV, intravenous.
Reference
EVRENZO™ (roxadustat), 20, 50, 70, 100 och 150 mg filmdragerade tabletter, B03XA05, Rx, F
▼Detta läkemedel är föremål för utökad övervakning. Detta kommer att göra det möjligt att snabbt identifiera ny säkerhetsinformation. Hälso- och sjukvårdspersonal uppmanas att rapportera varje misstänkt biverkning.
Indikationen är behandling av vuxna patienter med symtomatisk anemi associerad med kronisk njursjukdom (CKD). Kontraindikationer är överkänslighet mot den aktiva substansen, jordnötter, soja eller hjälpämne, användning under graviditetens 3e trimester samt amning. Varningar och försiktighet inkluderar risk för allvarliga kardiovaskulära och trombovaskulära händelser, krampanfall och allvarliga infektioner inklusive sepsis. Ska inte sättas in hos kvinnor som planerar att bli gravida eller under graviditet. Felanvändning kan leda till en överdrivet förhöjd hematokrit vilket kan leda till livshotande komplikationer i hjärt-kärlsystemet.
Astellas Pharma AB, Box 21046, 200 21 Malmö. Produktresumé 2022-09.
För ytterligare information och förpackningar se www.fass.se.